The ALB Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population targeting the ALB gene in the DLD-1 human colorectal adenocarcinoma cell line. This knockout model disrupts ALB expression, providing a loss-of-function platform for investigating albumin’s biological functions in a cancer context. The polyclonal format represents a mixed edited pool, suitable for bulk functional assays.
DLD-1 is a widely characterized adherent epithelial cell line derived from a human colorectal adenocarcinoma. It serves as a robust in vitro model for colorectal cancer research, maintaining key features of intestinal epithelial cells. The DLD-1 line is commonly used for studying cancer cell signaling, drug responses, and metabolic adaptations. Its well-documented genetic background and growth properties make it an ideal host for gene-editing studies.
ALB encodes serum albumin, a major plasma protein responsible for maintaining colloid osmotic pressure and transporting a diverse array of ligands including fatty acids, bilirubin, and steroid hormones. In the cellular context, albumin interacts with receptors such as gp60 and megalin/cubilin, and proteins like SPARC, influencing uptake and intracellular trafficking. ALB expression is regulated by transcription factors HNF1A, HNF4A, and CEBPA, and is modulated by inflammatory cytokines IL-6, TNF, and glucocorticoids. Downstream, albumin functionally converges with antioxidant enzymes SOD1 and CAT, and lipid metabolism regulators FASN and SREBF1, indicating its involvement in oxidative stress responses and fatty acid homeostasis.
In DLD-1 colorectal adenocarcinoma cells, ALB knockout provides a model to dissect albumin’s contribution to tumor cell metabolism and stress resilience. Loss of albumin may disrupt lipid transport and alter sensitivity to oxidative stress, mirroring conditions associated with hypoalbuminemia in cancer patients. This model enables examination of how albumin deficiency affects pathways governed by NRF2, FABP1, and SLC27A4, which are implicated in cellular detoxification and fatty acid utilization. Consequently, the knockout cells are valuable for validating albumin’s role as a potential prognostic marker in colorectal cancer.
Typical applications include studying albumin-mediated drug transport and binding, assessing oxidative stress responses, and evaluating lipid metabolism in colorectal cancer. This polyclonal knockout population is suitable for assays such as Western blotting, RT-qPCR, ELISA, cell viability assays, fatty acid uptake measurements, and migration or colony formation experiments. Researchers can employ these cells to explore how ALB loss influences chemosensitivity, signaling pathways, and metabolic rewiring. For additional technical information or customization options, please contact Ascent Research.
